Every 10-Q that ZOETIS INC. (ZTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZTS filings page.
Zoetis Inc. delivered stable first‑quarter 2026 results with modest top-line growth and flat profit. Revenue rose to $2,262 million from $2,198 million, a 3% increase that reflects a 4% foreign-exchange tailwind and a 1% decline on an operational basis.
Net income was essentially unchanged at $601 million, but diluted earnings per share increased to $1.42 from $1.34, helped by a lower share count after substantial buybacks. The company generated $401 million in cash from operations, down from $515 million, while investing $606 million in share repurchases and paying $224 million in cash dividends.
Zoetis ended the quarter with $1,941 million in cash and cash equivalents and $9,045 million in long-term debt, including $2,000 million of 0.250% convertible senior notes due 2029. Management highlighted a lower effective tax rate of 20.7% and continued use of non-GAAP metrics such as adjusted net income of $646 million to evaluate underlying performance.
Zoetis Inc. filed its Q3 2025 report, showing steady growth. Revenue was $2.4 billion versus $2.388 billion a year ago, and diluted EPS reached $1.63 compared with $1.50. Net income attributable to Zoetis rose to $721 million from $682 million as cost of sales declined and operating expenses remained well managed. For the first nine months, revenue was $7,080 million versus $6,939 million, with diluted EPS of $4.65 versus $4.18.
Companion animal products continued to lead, with Q3 category revenue of $1,652 million, while livestock was $725 million. By product, parasiticides ($564 million), vaccines ($496 million), and dermatology ($472 million) were top contributors. Cash and cash equivalents were $2,084 million, and long-term debt (net) was $7,069 million after issuing $1.85 billion of new senior notes to redeem 2025 maturities. The company repurchased $381 million of shares in Q3 and $1,169 million year to date. The effective tax rate improved to 18.7% from 20.8%.
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.